A lecturer from College of Education for Pure Sciences, University of Kerbala, Dr. Ammar Abdul Hussein Al-Qarawi, obtains a patent from Central Organization for Standardization and Quality Control for being able to manufacture a new pharmaceutical compound.
The patent includes preparation of a medicinal derivative of benzoic maleimide, replaced with cephalexin. The new medicinal compound is characterized by antibacterial activity that exceeds effectiveness of original drug by several times, almost non-existent cellular toxicity, and a very high ability to inhibit growth of cancer cells, with a concentration corresponding to half-inhibition rate of (IC50 = 6.22) micrograms. \ml.
The patent aims at developing a drug with dual biological activity to treat various infections, especially those that accompany cancerous diseases.
